> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# BMS/Qiagen Agreement on Immuno-oncology Products
- URL: https://www.fdaweb.com/bms-qiagen-agreement-on-immuno-oncology-products/
- Published: 2017-06-05T12:00:00.000Z
- Updated: 2026-09-14T22:27:22.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5138850

Bristol-Myers Squibb and Qiagen have entered into an agreement to explore using next-generation sequencing (NGS) technology to develop gene expression profiles (GEPs) as predictive or prognostic tools for use with BMS’ novel immuno-oncology (I-O) therapies in cancer treatment. The companies also plan to enter into a further agreement to “develop diagnostic products using the jointly developed GEPs and to expand the use of NGS technology with other Bristol-Myers Squibb I-O therapies,” they say.